CRISPR Therapeutics AG (CRSP) Dividend Safety Gauge & 10-Year DRIP Compounder
CRISPR Therapeutics AG (CRSP) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (55/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+61.2% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
$10,000 Compounded Over 10 Years → $17,081
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring CRSP)
- ✓Live walkthrough of CRSP's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
CRSP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CRSP today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CRSP. Explore sector supply chains on /butterfly.
CRSP Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDDoes CRSP pay a dividend and is it safe?
CRISPR Therapeutics AG (CRSP) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.